Sana Biotechnology
SANA
2.70
-0.02
-0.74%
Sana Biotechnology
US · SANA
#3404 by market cap
Listed 2021
2.70
-0.02
-0.74%
Live - 5344 symbols - heartbeat 316s ago
· 2026-10-08 09:59
Pre-market
2.72
0.00%
After-hours
2.80
+2.94%
Overnight
2.77
+1.84%
- Market cap
- 808.27M
- P/E (TTM)i
- -3.60
- P/Bi
- 5.23
- EPSi
- -0.96
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on SANA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 3.3 percentage points.
Institutional ownership
- Held by institutions
- 79.12% -3.34pp
- Institutions
- 241 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund34.19%
Mutual Fund31.68%
Individual/Insider6.30%
Public Company4.79%
Hedge Fund4.07%
Government Pension Fund3.62%
Private Company0.54%
Insurance Company0.12%
Family Office/Trust0.10%
Other14.59%
Top holders as of 2026-06-30
Arch Venture Partners, L.P.
15.32% · 45.86M sh
FMR
10.99% · 32.89M sh
Flagship Pioneering, Inc
8.35% · 25.00M sh
RA Capital Management, L.P.
6.26% · 18.75M sh
BlackRock
5.57% · 16.68M sh
State Street Global Advisors
3.74% · 11.20M sh
Canada Pension Plan Investment Board
3.41% · 10.22M sh
Vanguard Capital Management, LLC
3.21% · 9.61M sh
Steven Harr
2.99% · 8.96M sh
Hans Edgar Bishop
1.96% · 5.85M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 37 buys · 10 sells
| Name | Role | Stake |
|---|---|---|
| Arch Venture Partners, L.P. | -- | 15.32% |
| Steven Harr | Chief Executive Officer | 2.99% |
| Hans Edgar Bishop | Independent Chairperson | 1.96% |
| Richard Mulligan | Executive Vice Chairman & Head of Innovation Research | 0.90% |
| Nathan Hardy | Chief Financial Officer | 0.15% |
| Douglas Cole | Independent Director | 0.07% |
| Susan Wyrick | Acting CFO, Treasurer, Principal Accounting Officer and Senior VP of Finance & Accounting | 0.07% |
| Dhavalkumar Patel | Chief Scientific Officer | 0.06% |
| Yuhmin Yang | Independent Director | 0.05% |
| Bernard Cassidy | General Counsel | 0.04% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-26 | Dhavalkumar Patel | Chief Scientific Officer | Derivative Exercise and Sale | -41,158 | $4.11 |
| 2026-08-25 | Dhavalkumar Patel | Chief Scientific Officer | Derivative Exercise and Retained | +83,842 | -- |
| 2026-07-05 | Hans Edgar Bishop | Independent Chairperson | Other Acquisition | +6,297 | -- |
| 2026-06-03 | Robert Taylor Nelsen | Independent Director | Other Derivative Acquisition | +90,000 | $2.96 |
| 2026-06-03 | Yuhmin Yang | Independent Director | Other Derivative Acquisition | +90,000 | $2.96 |
| 2026-06-03 | Michelle Seitz | Independent Director | Other Derivative Acquisition | +90,000 | $2.96 |
| 2026-06-03 | Richard Mulligan | Executive Vice Chairman & Head of Innovation Research | Other Derivative Acquisition | +90,000 | $2.96 |
| 2026-06-03 | Hans Edgar Bishop | Independent Chairperson | Other Derivative Acquisition | +90,000 | $2.96 |
| 2026-06-03 | Joshua Bilenker | Independent Director | Other Derivative Acquisition | +90,000 | $2.96 |
| 2026-06-03 | Alise Reicin | Independent Director | Other Derivative Acquisition | +90,000 | $2.96 |
| 2026-06-03 | Robert Rosiello | Director | Other Derivative Acquisition | +90,000 | $2.96 |
| 2026-04-05 | Hans Edgar Bishop | Independent Chairperson | Other Acquisition | +7,763 | -- |
| 2026-03-23 | Dhavalkumar Patel | Chief Scientific Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-08 | Steven Harr | Chief Executive Officer | Derivative Exercise and Sale | -24,345 | $3.10–3.13 |
| 2026-03-08 | Susan Wyrick | Acting CFO, Treasurer, Principal Accounting Officer and Senior VP of Finance & Accounting | Derivative Exercise and Sale | -4,387 | $3.10–3.13 |
| 2026-03-06 | Steven Harr | Chief Executive Officer | Derivative Exercise and Retained | +67,321 | -- |
| 2026-03-05 | Susan Wyrick | Acting CFO, Treasurer, Principal Accounting Officer and Senior VP of Finance & Accounting | Derivative Exercise and Retained | +9,279 | -- |
| 2026-03-04 | Steven Harr | Chief Executive Officer | Other Derivative Acquisition | +200,000 | -- |
| 2026-03-04 | Steven Harr | Chief Executive Officer | Other Derivative Acquisition | +900,000 | $3.41 |
| 2026-03-04 | Susan Wyrick | Acting CFO, Treasurer, Principal Accounting Officer and Senior VP of Finance & Accounting | Other Derivative Acquisition | +45,833 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:59:55 · For reference only, not investment advice and not tailored to your situation.